search
Back to results

ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain (qlcsection)

Primary Purpose

Pain, Postoperative

Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
ITM + Sham QLB
ITM + Bupivacaine QLB
Sponsored by
Nicholas Schott
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative focused on measuring quadratus lumborum block, post-operative pain, cesarean section pain, analgesia, nerve block

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Elective cesarean planned under spinal anesthesia
  • Singleton pregnancy
  • American Society of Anesthesiologists (ASA) classification score of 2 (or less)
  • Gestational age of at least 37 weeks
  • Intention to breastfeed infant

Exclusion Criteria:

  • Contraindications to neuraxial blockade (such as clinically relevant coagulopathy, recent anticoagulant use, patient refusal, or localized skin infection overlying the site of needle entry)
  • Anatomical abnormalities contraindicating spinal or QLB placement
  • Received/Conversion to general anesthesia
  • Received supplemental parenteral anesthesia (sedation) for any reason (e.g. unanticipated prolonged surgical procedure)
  • History of chronic pain
  • History of chronic opioid use/abuse
  • History of Subutex, methadone, other maintenance therapy

Sites / Locations

  • Magee Women's Hospital of UPMCRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Sham Comparator

Experimental

Arm Label

ITM + Sham QLB

ITM + Bupivacaine QLB

Arm Description

Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.

Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.

Outcomes

Primary Outcome Measures

VAS pain score with movement
Post-operative pain accompanied with patient movement will be measured using a 10 point pain scale (VAS)

Secondary Outcome Measures

Breast feeding success/quality
Limited breastfeeding resulting from pain or opioid side effects
VAS pain score at rest
VAS pain score reported by the patient at rest post-operatively using a 10 point pain scale (VAS)
First request for pain medication
Time to first request for as desired (PRN) oral or parenteral opioid medication will be assessed
Sedation
Presence or absence will be noted
Pruritis
Presence or absence will be noted
Nausea
Presence or absence will be noted
Emesis
Presence or absence will be noted
Heart Rate
Will be measured in beats/minute (BPM) per standard of care and documented by study staff
Anesthetic toxicity
symptoms indicating this event such as perioral numbness, ringing in the ears or metallic taste in the mouth will be noted
Blood pressure
Will be measured in mmHG per standard of care and documented by study staff
Respiratory Rate
Will be measured in rate/min per standard of care and documented by study staff
Oxygen Saturation
Will be measured in % per standard of care and documented by study staff
36-Item Short Form Survey (SF-36)
Quality of life measures will be assessed using the SF-36
Brief Pain Inventory (BPI) - Short Form
Severity of pain and its impact on functioning using BPI Short Form
Edinburgh Postnatal Depression Scale (EPDS)
Possible symptoms of depression in the postnatal period will be assessed via EPDS
Dynamic Pain Visual Analogue scale
Pain score reported by the patient at rest using the VAS scale
Opioid use
Total opioid consumption post-operative

Full Information

First Posted
July 27, 2017
Last Updated
June 2, 2022
Sponsor
Nicholas Schott
search

1. Study Identification

Unique Protocol Identification Number
NCT03261193
Brief Title
ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain
Acronym
qlcsection
Official Title
QL Block for Post-cesarean Delivery Pain
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 5, 2017 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Nicholas Schott

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Comparison of standard post-operative cesarean surgery pain management with regional post-op pain control.
Detailed Description
The purpose of this trial is to determine the efficacy of a postoperative analgesia strategy that incorporates quadratus lumborum block (QLB) in conjunction with a multi-modal post-cesarean analgesia strategy. The investigators hypothesize that QLB will provide superior post-cesarean analgesia compared to the current standard of care, multi-modal analgesia. Thus, analgesia following cesarean section using QLB compared to the current standard of care alone will be further investigated. Current practice for cesarean surgical intervention consists of multi-modal analgesia (i.e., Intrathecal morphine (ITM) and scheduled post-operative non-opioid oral analgesics, with oral opioid analgesics reserved for breakthrough pain). Investigators will measure side-effects associated with each strategy: Standard of care methods consisting of intrathecal morphine (ITM) plus scheduled non-opioid analgesics in conjunction with prn opioid analgesics for breakthrough pain will be utilized for both. The experimental treatment arm will entail standard of care in addition to QLB. The sham comparator will entail standard of care in addition to QLB with saline. For each strategy, we will measure and model associated economic ramifications; such factors will include drug costs, procedure costs, and costs associated with length of stay and re-admissions. The quadratus lumborum block (QLB) is similar to the transversus abdominis plane (TAP) block, but differs slightly in regards to the anatomical region where local anesthetic is injected. Since the quadratus lumborum (QL) is more posteriorly located, it theoretically confers greater safety due to enhanced visualization. The TAP block has been studied extensively for post-cesarean delivery pain, consistently showing that it is not superior to ITM for post-operative analgesia; however, it may prove to be helpful in patients with breakthrough pain despite the use of ITM, or in patients who were unable to receive ITM (e.g. general anesthesia for cesarean, contraindications to neuraxial morphine). Thus, ITM is superior to TAP alone for post-cesarean analgesia, but it is associated with a dose-dependent increased risk for opioid related side effects. In 2015, Blanco et. al. published a study specifically using the QLB for postoperative pain after cesarean delivery. In this study, they compared a true QLB to a sham QLB all in patients who did not receive ITM, and found that the QLB provided improved pain control and decreased the need for post-operative opioids. Another study in 2016 demonstrated that the QLB is superior to the TAP block in regards to decreasing post-operative pain following c-section. Unfortunately, neither study compared the QLB to ITM (part of the current gold standard for post-cesarean delivery pain, multimodal analgesia). The gap in knowledge regarding the utility of QLB as part of a multimodal analgesic approach including ITM for cesarean section warrants further investigation. Clinicians are constantly searching for methods to provide patients with the most effective medical interventions that provide maximal benefit and minimal harm. Post-operative pain control following cesarean delivery is an area that is important to patients and to providers, and the introduction of the QLB for this purpose has the potential to improve analgesic benefit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative
Keywords
quadratus lumborum block, post-operative pain, cesarean section pain, analgesia, nerve block

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ITM + Sham QLB
Arm Type
Sham Comparator
Arm Description
Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.
Arm Title
ITM + Bupivacaine QLB
Arm Type
Experimental
Arm Description
Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.
Intervention Type
Drug
Intervention Name(s)
ITM + Sham QLB
Other Intervention Name(s)
Saline
Intervention Description
Sham subcutaneous non-anesthetic infiltration with saline
Intervention Type
Drug
Intervention Name(s)
ITM + Bupivacaine QLB
Other Intervention Name(s)
Bupivacaine
Intervention Description
QL plane block with local anesthesia
Primary Outcome Measure Information:
Title
VAS pain score with movement
Description
Post-operative pain accompanied with patient movement will be measured using a 10 point pain scale (VAS)
Time Frame
24 hours after surgical procedure (cesarean delivery)
Secondary Outcome Measure Information:
Title
Breast feeding success/quality
Description
Limited breastfeeding resulting from pain or opioid side effects
Time Frame
12, 24 and 36 hours post-operatively
Title
VAS pain score at rest
Description
VAS pain score reported by the patient at rest post-operatively using a 10 point pain scale (VAS)
Time Frame
At baseline (PACU entry) and 1, 4, 24 and 48 hours after intervention
Title
First request for pain medication
Description
Time to first request for as desired (PRN) oral or parenteral opioid medication will be assessed
Time Frame
From post-operative until the patient is either withdrawn from the study or requests analgesic medication up until 72 hours
Title
Sedation
Description
Presence or absence will be noted
Time Frame
From post-operative until the patient is either withdrawn from study or experiences this event up until 72 hours
Title
Pruritis
Description
Presence or absence will be noted
Time Frame
From post-operative until the patient is either withdrawn from study or experiences this event up until 72 hours
Title
Nausea
Description
Presence or absence will be noted
Time Frame
From post-operative until the patient is either withdrawn from study or experiences this event up until 72 hours
Title
Emesis
Description
Presence or absence will be noted
Time Frame
From post-operative until the patient is either withdrawn from study or experiences this event up until 72 hours
Title
Heart Rate
Description
Will be measured in beats/minute (BPM) per standard of care and documented by study staff
Time Frame
From post-operative every 24 hours until the patient is either withdrawn from or completes the study, on average 72 hours
Title
Anesthetic toxicity
Description
symptoms indicating this event such as perioral numbness, ringing in the ears or metallic taste in the mouth will be noted
Time Frame
15 min, 30 min, 45 min, 1 hour, and 4 hours post-operatively
Title
Blood pressure
Description
Will be measured in mmHG per standard of care and documented by study staff
Time Frame
From post-operative every 24 hours until the patient is either withdrawn from or completes the study, on average 72 hours
Title
Respiratory Rate
Description
Will be measured in rate/min per standard of care and documented by study staff
Time Frame
From post-operative every 24 hours until the patient is either withdrawn from or completes the study, on average 72 hours
Title
Oxygen Saturation
Description
Will be measured in % per standard of care and documented by study staff
Time Frame
From post-operative every 24 hours until the patient is either withdrawn from or completes the study, on average 72 hours
Title
36-Item Short Form Survey (SF-36)
Description
Quality of life measures will be assessed using the SF-36
Time Frame
48-hours post-operatively
Title
Brief Pain Inventory (BPI) - Short Form
Description
Severity of pain and its impact on functioning using BPI Short Form
Time Frame
6-weeks post operatively
Title
Edinburgh Postnatal Depression Scale (EPDS)
Description
Possible symptoms of depression in the postnatal period will be assessed via EPDS
Time Frame
6-weeks post operatively
Title
Dynamic Pain Visual Analogue scale
Description
Pain score reported by the patient at rest using the VAS scale
Time Frame
6-weeks postoperatively
Title
Opioid use
Description
Total opioid consumption post-operative
Time Frame
From post-operative until 36 hours and at 6-weeks postoperatively or until the patient is discharged or withdrawn from study

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
pregnancy
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Elective cesarean planned under spinal anesthesia Singleton pregnancy American Society of Anesthesiologists (ASA) classification score of 2 (or less) Gestational age of at least 37 weeks Intention to breastfeed infant Exclusion Criteria: Contraindications to neuraxial blockade (such as clinically relevant coagulopathy, recent anticoagulant use, patient refusal, or localized skin infection overlying the site of needle entry) Anatomical abnormalities contraindicating spinal or QLB placement Received/Conversion to general anesthesia Received supplemental parenteral anesthesia (sedation) for any reason (e.g. unanticipated prolonged surgical procedure) History of chronic pain History of chronic opioid use/abuse History of Subutex, methadone, other maintenance therapy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nicholas Schott
Phone
7168807034
Email
schottnj@upmc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Stephanie Nam
Email
nams@upmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy Monroe
Organizational Affiliation
University of Pittsburgh
Official's Role
Study Director
Facility Information:
Facility Name
Magee Women's Hospital of UPMC
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No plans to share

Learn more about this trial

ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain

We'll reach out to this number within 24 hrs